Sun eclipsed by Wyeth's 'exaggerated' damages claim in Protonix case
This article was originally published in Scrip
Executive Summary
Shares of Sun Pharmaceutical Industries ended lower on Indian bourses after the firm said that Wyeth was claiming damages of $960 million in a case concerning generic Protonix (pantoprazole), though analysts believe that the "exaggerated" claim was unlikely to pass court muster.